Bone healing process in critical-sized defects by rhBMP-2 using poloxamer gel and collagen sponge as carriers.
The bone morphogenetic protein type 2, is an osteoinduction protein, but new carriers to improve its actions are being studied in recent researches. The objective of this study was to evaluate the poloxamer gel as potential carrier of the rhBMP-2 during the bone healing process and verify if the collagen sponge can improve this process. Fifty-six male Wistar rats were used, which were divided into two groups, considering two periods of time. Thus, each one of these groups was divided in four groups with seven animals each, according to the treatment and the defect filled by 4 microg rhBMP-2 in aqueous solution, 4 microg rhBMP-2 in aqueous solution+collagen sponge, 4 microg rhBMP-2 combined with poloxamer gel, and 4 microg rhBMP-2 combined with poloxamer gel+collagen sponge. After 2 and 4 weeks, respectively, animals were perfused and the hemi-mandibles removed for histological analysis. Statistical analysis of the data showed significant difference between all analyzed groups (p<0.01), and between the periods of time (p=0.0118). There was no interaction between the applied treatment and considered periods of time (p=0.642). Results showed that the rhBMP-2 used in this study was able to induce bone regeneration and had its action optimized when combined to the used carriers, being the bone repair time-dependent.
Issa
João Paulo Mardegan
JP
Faculty of Dentistry, University of São Paulo, Ribeirão Preto, São Paulo, Brazil. jpmissa@forp.usp.br
do Nascimento
Cássio
C
Iyomasa
Mamie Mizusaki
MM
Siéssere
Selma
S
Regalo
Simone Cecílio Hallak
SC
Defino
Helton Luiz Aparecido
HL
Sebald
Walter
W
D000818:Animals; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D003094:Collagen / Q000008:administration & dosage / Q000627:therapeutic use*; D004337:Drug Carriers / Q000627:therapeutic use*; D006651:Histocytochemistry; D008297:Male; D008334:Mandible / Q000166:cytology; D010012:Osteogenesis / Q000187:drug effects / Q000502:physiology*; D010027:Osteotomy; D020442:Poloxamer / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D016212:Transforming Growth Factor beta / Q000008:administration & dosage / Q000627:therapeutic use*
C525720:Bmp2 protein, rat; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D004337:Drug Carriers; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D020442:Poloxamer; D003094:Collagen